Clinical Trials
36 trialsUsing Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
LUPARPED
FundaciĆ³n de investigaciĆ³n HM
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
GoTHAM
Melanoma and Skin Cancer Trials Limited
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
NELMAS
Imperial College London
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
LANTana
Imperial College London
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
AHS Cancer Control Alberta
LUMOD-ID
University of Iowa
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
DOBATOC
University of Aarhus
Lu-DOTA-TATE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
P-PRRT
CHU de Quebec-Universite Laval
SPORE-3
University of Iowa
NeoLuPaNET
IRCCS San Raffaele
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Peking University
Radio-Marker
Erasmus Medical Center
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Excel Diagnostics and Nuclear Oncology Center
SEPTRALU
Sociedad EspaƱola de Medicina Nuclear e Imagen Molecular
LUMEN
Jules Bordet Institute
LUTIA
UMC Utrecht
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
FundaciĆ³n de investigaciĆ³n HM
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
CHARRT
King's College Hospital NHS Trust
POLNETS_PRRT
University of Warmia and Mazury
CASTOR
Jules Bordet Institute
NEO-LEBE
University of Jena